Mathews Journal of Case Reports


Previous Issues Volume 8, Issue 7 - 2023

Cytokine-Induced Neurogenesis in Charcot-Marie-Tooth neuropathy with Connexin 32 Gene Mutation

Takuji Shirasawa1,2,*, Luis Carlos Aguilar Cobos3

1Ochanomizu Health and Longevity Clinic, Tokyo, Japan

2Shirasawa Anti-Aging Medical Institute, Tokyo, Japan

3Livant Neurorecovery Center, Guadalajara, Mexico

*Corresponding author: Takuji Shirasawa, Shirasawa Anti-Aging Medical Institute, Sagawa BLD 701, KandaSurugadai 2-8, Chiyoda-Ku, Tokyo 101-0062, Japan; E-mail: [email protected]

Received Date: May 12, 2023

Publication Date: June 1, 2023

Citation: Shirasawa T, et al. (2023). Cytokine-Induced Neurogenesis in Charcot-Marie-Tooth neuropathy with Connexin 32 Gene Mutation. Mathews J Case Rep. 8(7):118.

Copyright: Shirasawa T, et al. © (2023)


Charcot-Marie-Tooth (CMT) neuropathy is one of the most common neuromuscular disorders. Despite the identification of more than 100 causative genes, there are few therapeutic options. We present the case of a 66-year-old man carrying a CMT mutation in the connexin 32 gene with the APOE genotype ε4/ε3 that had exhibited symptoms of slowly progressive muscle weakness and atrophy in the hands and feet and recently developed memory impairment. The muscle weakness, motor dysfunction, and memory impairment symptoms were significantly improved by cytokine-induced neurogenesis combined with physical wave therapy using an arbitrary waveform generator (AWG). Here, we discuss the possible mechanistic basis of how this new treatment ameliorates the symptoms of CMT and propose a novel clinical treatment strategy for CMT.

Keywords: Charcot-Marie-Tooth (CMT) neuropathy, cytokine, wave therapy, neurogenesis, connexin 32

Creative Commons License

© 2015 Mathews Open Access Journals. All Rights Reserved.

Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at